News & Events

New drug approved for the treatment of High Risk Neuroblastoma

By chfadmin Monday, 15th July 2019 | 0 comments
Filed under: News, Hospital, Awareness, Advocacy.
Childhood Cancer Foundation is delighted to see that “Dinutuximab Beta”, an innovative immunotherapy drug for the treatment of High Risk Neuroblastoma, has been approved for reimbursement in Ireland. To date, this has only been available as part of clinical trials. This ground breaking drug will now become part of the frontline “standard of care” for Irish children with High Risk Neuroblastoma.  This puts Irish children on a par with children receiving the most up to date front line treatments available across the world.